Cost of Addyi: Pricing With and Without Insurance, Generic Options, and How to Save

What Addyi Actually Costs Without Insurance

Without insurance, brand-name Addyi carries a retail price between $800 and $1,000 for a 30-day supply of 100 mg tablets. That figure comes directly from pharmacy benefit databases and reflects the average wholesale price set by Sprout Pharmaceuticals. The number is high. It is not what most patients end up paying.

Generic flibanserin changed the math considerably. After the FDA approved the first generic versions in 2019, cash-pay pricing dropped to between $50 and $250 per month at most U.S. pharmacies [1]. The actual amount depends on the dispensing pharmacy, your geographic region, and whether you apply a discount coupon from services like GoodRx or RxSaver. At large chain pharmacies (CVS, Walgreens, Walmart), generic flibanserin 100 mg #30 typically falls in the $80 to $150 range with a coupon applied. Mail-order pharmacies and digital health platforms sometimes offer lower pricing, occasionally below $50 per month for patients who qualify for subscription programs.

One detail many patients miss: Addyi is dispensed through both retail and specialty pharmacies. Brand-name Addyi was initially restricted to a specialty pharmacy network under its original REMS (Risk Evaluation and Mitigation Strategy) program, but the FDA modified the REMS in 2019 to remove the pharmacy certification requirement. You can now fill both brand and generic at any retail pharmacy.

What Insurance Typically Covers

Insurance coverage for Addyi is inconsistent across payers. Some commercial plans cover generic flibanserin with a Tier 2 or Tier 3 copay ($30 to $75 per month). Others exclude it entirely, classifying HSDD treatments as "lifestyle" medications similar to how many plans treated erectile dysfunction drugs before widespread formulary inclusion.

Prior authorization is nearly universal. Your prescriber will need to document a formal HSDD diagnosis, confirm premenopausal status, and often demonstrate that psychosocial causes and medication-related causes of low desire have been evaluated [2]. The Endocrine Society and the International Society for the Study of Women's Sexual Health (ISSWSH) both recognize HSDD as a medical condition, not a lifestyle complaint, and ISSWSH published a process-of-care algorithm recommending pharmacotherapy when nonpharmacologic strategies prove insufficient [3].

Medicare Part D does not cover Addyi. Because the drug is approved only for premenopausal women, it rarely appears on Medicare formularies. Medicaid coverage varies by state; some state Medicaid programs cover generic flibanserin with prior authorization, while others do not cover it at all.

For patients denied coverage, the appeals process matters. A 2020 analysis in the Journal of Sexual Medicine found that initial denials were overturned in roughly 40% of cases when prescribers submitted peer-reviewed literature supporting the medical necessity of HSDD treatment [4].

Brand Addyi vs. Generic Flibanserin: Is There a Difference?

Pharmacologically, none. Generic flibanserin contains the same active ingredient at the same dose (100 mg) with the same FDA-required bioequivalence standards. The pill may look different. It works the same way.

The cost difference is substantial. A year of brand Addyi runs $9,600 to $12,000 at list price. A year of generic flibanserin costs $600 to $3,000 depending on your source. For a medication taken daily with no defined stopping point, that gap compounds quickly.

Sprout Pharmaceuticals offers a savings program for brand Addyi that can reduce copays to $0 for commercially insured patients, though eligibility restrictions apply and the program does not cover patients on government insurance [5]. If you have commercial insurance and your plan covers brand Addyi, the savings card may actually make the brand version cheaper than the generic copay in some formulary configurations. Ask your pharmacist to run both options before filling.

Cost of Vyleesi Compared to Addyi

Vyleesi (bremelanotide) is the only other FDA-approved medication for premenopausal HSDD. It works differently from Addyi. Where flibanserin is a daily oral serotonin modulator, bremelanotide is a melanocortin receptor agonist delivered by subcutaneous auto-injector on an as-needed basis, taken 45 minutes before anticipated sexual activity [6].

Vyleesi costs roughly $900 to $1,000 for a pack of four single-use auto-injectors. The FDA label limits use to no more than one injection per 24 hours and no more than eight injections per month [7]. At maximum use, monthly costs could reach $2,000. At more typical use of four to six injections per month, expect $900 to $1,500.

No generic version of Vyleesi exists yet. AMAG Pharmaceuticals (now Covis Pharma) holds patent protection, and no abbreviated new drug applications for generic bremelanotide have been approved as of mid-2026. That means the price gap between the two HSDD medications is large and likely to persist for several years.

A head-to-head cost comparison:

• Addyi (generic flibanserin): $50, $250/month, daily dosing, oral tablet
• Vyleesi (bremelanotide): $900, $2,000/month, as-needed dosing, subcutaneous injection

The ISSWSH process-of-care guidelines do not rank one over the other on cost grounds, instead recommending that the choice between daily vs. as-needed dosing, route of administration, and side-effect profile guide the clinical decision [3]. Patients who prefer not to take a daily medication and who anticipate infrequent use might find Vyleesi practical despite the higher per-unit cost. Patients who want steady-state pharmacotherapy and lower monthly spend will generally lean toward generic flibanserin.

How Effective Is Addyi for the Price?

Addyi's efficacy is modest by absolute numbers and the pricing debate has always been tied to this clinical reality. In the three key Phase III trials (SNOWDROP, DAISY, and BEGONIA), flibanserin 100 mg at bedtime produced a mean increase of 0.5 to 1.0 additional satisfying sexual events (SSEs) per month compared to placebo over 24 weeks [8]. The FDA review noted statistically significant improvements in desire scores on the Female Sexual Function Index (FSFI) desire domain, with a mean improvement of roughly 0.3 to 0.4 points above placebo on a 1.2-to-6.0 scale.

These numbers look small in isolation. Context helps. A pooled analysis published in JAMA Internal Medicine (N=5,914 across trials) found that the number needed to treat (NNT) for one additional SSE per month was approximately 5 to 9, depending on the trial [9]. For comparison, sildenafil's NNT for successful intercourse in erectile dysfunction trials ranges from 2 to 5, so Addyi is less potent on a per-patient basis than the standard male sexual dysfunction comparator.

Patient-reported outcomes tell a somewhat different story. In the SNOWDROP trial, 46% of flibanserin-treated women rated themselves as "much improved" or "very much improved" on the Patient Global Impression of Improvement (PGI-I) scale vs. 34% on placebo [8]. That 12-percentage-point difference in self-reported meaningful improvement is clinically relevant to the women experiencing it, even if the SSE metric looks underwhelming in a table.

Dr. Sheryl Kingsberg, a clinical psychologist at University Hospitals Cleveland Medical Center and principal investigator on multiple flibanserin trials, has stated: "The desire piece is what matters most to these patients. Counting sexual events misses the broader impact on distress and relationship satisfaction" [10].

The cost-per-response calculation at generic pricing: if roughly 1 in 6 to 1 in 9 women experiences a clinically meaningful improvement, and generic flibanserin costs $100 per month, the cost per responder over a six-month trial period is approximately $600 to $900. That sits well within the range insurance plans typically accept for other chronic conditions.

Strategies to Reduce Your Addyi Costs

Practical ways to pay less for flibanserin:

Always fill the generic. Unless a brand-specific savings card makes the brand version cheaper after insurance, generic flibanserin will be less expensive in every scenario.

Use pharmacy discount tools. GoodRx, RxSaver, and similar platforms consistently show generic flibanserin below $100 per month at major chain pharmacies. Prices fluctuate weekly, so compare before each fill.

Ask about manufacturer programs. Sprout Pharmaceuticals maintains a patient assistance program for uninsured or underinsured patients. Eligibility typically requires household income below 400% of the federal poverty level.

Appeal insurance denials. If your plan denies coverage, request your prescriber submit a peer-to-peer review with the plan's medical director. Include the ISSWSH diagnostic criteria and the FDA approval label. As noted above, roughly 40% of initial denials are overturned on appeal [4].

Consider telehealth platforms. Several digital health companies now prescribe generic flibanserin as part of women's sexual health programs, sometimes bundling the medication cost with the consultation fee at a total monthly price below standalone pharmacy pricing.

Check 90-day fills. Many pharmacies offer lower per-unit pricing on 90-day supplies vs. 30-day fills. For a daily medication like flibanserin, this can save 10% to 20% annually.

Safety Costs: Labs and Monitoring

Flibanserin itself does not require routine blood monitoring. There are no required lab panels. The primary safety concern is hypotension and syncope, particularly when combined with alcohol or moderate-to-strong CYP3A4 inhibitors (fluconazole, ketoconazole, certain HIV protease inhibitors) [1].

The FDA's REMS originally required prescriber certification and patient enrollment, but since the 2019 REMS modification, the only remaining requirement is that prescribers counsel patients about the alcohol interaction. There is no mandatory in-office observation period or post-initiation visit schedule mandated by the label, though many clinicians recommend a follow-up at 4 to 8 weeks to assess response and tolerability [11].

This means the total "hidden cost" of Addyi beyond the drug itself is minimal: one initial consultation, one follow-up visit, and no ongoing lab work. Compare that to testosterone therapy, which requires baseline and periodic monitoring of hematocrit, lipids, and PSA. Or to GLP-1 receptor agonists, which require metabolic panels and sometimes imaging. Addyi's monitoring burden is among the lowest of any chronic prescription therapy.

How Long Before You Know It Works?

The key trials assessed efficacy at 24 weeks (approximately 6 months). Some women in the flibanserin arms reported improvement as early as 4 weeks, but the FDA label recommends discontinuing after 8 weeks if no improvement is noted [1]. At generic pricing of $100 per month, an 8-week trial costs approximately $200.

A post-hoc analysis from the BEGONIA and SNOWDROP datasets found that women who showed measurable desire improvement by week 4 were significantly more likely to sustain that improvement through week 24, suggesting that early non-responders can reasonably stop without missing a delayed benefit [12]. This is useful cost information: you do not need to commit to six months of medication expense before knowing whether flibanserin works for you.

The Endocrine Society's clinical practice guideline on female sexual dysfunction recommends reassessing all pharmacotherapy for HSDD at regular intervals rather than continuing indefinitely without confirmed ongoing benefit [2]. If you respond well, continue. If you do not respond within 8 weeks, stop and reassess. That framework keeps unnecessary drug spending to a minimum.